Evidence map›Paper›PMID 37483602›Full record

ArticleFrontiers in immunology2023

Editorial: Global excellence in inflammatory diseases: North America 2021.

Linda L Kusner, Ravi S Misra, Rudolf Lucas

Abstract readEditorial
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in immunology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Linda L KusnerThe Laboratory for Myasthenia Gravis Research, Pharmacology and Physiology, The George Washington University, Washington, DC, United States.
Ravi S MisraDepartment of Pediatrics-Neonatology, University of Rochester-Golisano Children's Hospital, Rochester, NY, United States.
Rudolf LucasVascular Biology Center, Department of Pharmacology and Toxicology, Augusta University, Augusta, GA, United States.

Funding

Rare Disease Network for Myasthenia GravisU54NS115054 · NINDS · GEORGE WASHINGTON UNIVERSITY · PI Linda Louise Kusner · 2019 to 2026
$11.9M
BioRepository for INvestigation of Diseases of the Lung (BRINDL) - Phase IIIU01HL148861 · NHLBI · UNIVERSITY OF ROCHESTER · PI GLORIA S PRYHUBER · 2019 to 2026
$9.7M
The Human Lung BioMolecular Multi-Scale Atlas Program (HuBMAP-Lung)U54HL165443 · NHLBI · UNIVERSITY OF ROCHESTER · PI PRYHUBER, GLORIA S · 2022 to 2025
$8.0M
ENaC-α mediates lung fluid clearance and capillary barrier function in pneumoniaR01HL138410 · NHLBI · AUGUSTA UNIVERSITY · PI LUCAS, RUDOLF · 2018 to 2021
$2.0M
NHLBI NIH HHS R01 HL138410NHLBI NIH HHS U01 HL148861NHLBI NIH HHS U54 HL165443NINDS NIH HHS U54 NS115054
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Myasthenia GravisHumansNorth Americaautoimmune myasthenia gravise-cigarettegranulopoiesisinterstitial fibrosis and tubular atrophymelanomaolfactory receptorspulmonary hypertension

Identifiers

PMID37483602
PMCPMC10359722

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.